Abcam, ab181406, Anti-CD272/BTLA antibody

Size: 100µg
Rabbit Polyclonal CD272/BTLA antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human BTLA.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human BTLA. The exact immunogen used to generate this antibody is proprietary information.Q7Z6A9

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.2Preservative: 0.02% Sodium azideConstituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD272 also known as BTLA (B and T Lymphocyte Attenuator) is an immunoregulatory protein with a mass approximately 34 kDa. This target is part of the CD28 immunoglobulin superfamily and is expressed on the surfaces of various immune cells including T cells B cells and dendritic cells. BTLA/CD272 serves as a co-inhibitory molecule important in maintaining immune homeostasis. Its expression is influenced by factors present in the microenvironment of immune tissues.
Biological function summary
BTLA functions as a negative regulator of immune responses by delivering inhibitory signals to immune cells upon binding to its ligand HVEM (Herpesvirus entry mediator). It forms a part of an immunological checkpoint complex that modulates lymphocyte activity to prevent overactivation and autoimmunity. This mechanism helps maintain a balance between immune defense and tolerance contributing to self-tolerance.
Pathways
The BTLA/CD272 protein engages with pathways involved in immune checkpoints and T-cell receptor signaling. It interacts with proteins like HVEM and collaborates with receptors such as PD-1 and CTLA-4. These interactions play a role in the downregulation of T-cell responses which is essential in various immune processes. The signaling pathways influenced by BTLA/CD272 are integral in moderating immune responses cooperation and adaptation.
BTLA is associated with autoimmune diseases and cancer. In autoimmune disorders an altered expression or function of BTLA can lead to dysregulated immune responses causing tissue damage. In cancer the protein may contribute to immune evasion by tumors aiding tumor growth and progression. The interplay of BTLA with proteins such as PD-1 makes it a potential target for immunotherapy strategies in oncology and autoimmunity treatments.